These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33802015)

  • 1. Temporal Trends of Bleeding Episodes during Half- vs. Standard-Dose Ticagrelor in Acute Coronary Syndrome Patients with Low Platelet Reactivity: A Randomized BLEEDING-ACS Trial.
    Kim L; Choe JC; Ahn JH; Lee HW; Oh JH; Choi JH; Lee HC; Cha KS; Hong TJ; Jeong YH; Park JS
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33802015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome.
    Kang MG; Ahn JH; Kim K; Koh JS; Park JR; Hwang SJ; Park Y; Tantry US; Gurbel PA; Hwang JY; Jeong YH
    Front Cardiovasc Med; 2022; 9():1053867. PubMed ID: 36578832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
    Ge Z; Kan J; Gao X; Raza A; Zhang JJ; Mohydin BS; Gao F; Shao Y; Wang Y; Zeng H; Li F; Khan HS; Mengal N; Cong H; Wang M; Chen L; Wei Y; Chen F; Stone GW; Chen SL;
    Lancet; 2024 May; 403(10439):1866-1878. PubMed ID: 38599220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized non-inferiority study of low-dose and standard-dose ticagrelor after intervention for acute coronary syndrome: study protocol for the TIGER STUDY.
    Pang Y; Ma M; Xia J; Wang D; YanChen ; Ye J; Jia Z; Wu S; Yang J; Hou L
    Trials; 2022 Mar; 23(1):203. PubMed ID: 35248132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
    Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
    Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events.
    Alexopoulos D; Stavrou K; Koniari I; Gkizas V; Perperis A; Kontoprias K; Vogiatzi C; Bampouri T; Xanthopoulou I
    Thromb Haemost; 2014 Sep; 112(3):551-7. PubMed ID: 24990396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study.
    Jin C; Kim MH; Bang J; Serebruany V
    Cardiology; 2017; 138(4):201-206. PubMed ID: 28810251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial.
    Tomaniak M; Chichareon P; Klimczak-Tomaniak D; Takahashi K; Kogame N; Modolo R; Wang R; Ono M; Hara H; Gao C; Kawashima H; Rademaker-Havinga T; Garg S; Curzen N; Haude M; Kochman J; Gori T; Montalescot G; Angiolillo DJ; Capodanno D; Storey RF; Hamm C; Vranckx P; Valgimigli M; Windecker S; Onuma Y; Serruys PW; Anderson R
    Clin Res Cardiol; 2020 Jul; 109(7):930-943. PubMed ID: 31925529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
    Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
    Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor monotherapy for acute coronary syndrome: an individual patient data meta-analysis of TICO and T-PASS trials.
    Lee YJ; Shin S; Kwon SW; Suh Y; Yun KH; Kang TS; Lee JW; Cho DK; Park JK; Bae JW; Kang WC; Kim S; Lee SJ; Hong SJ; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Eur Heart J; 2024 Sep; 45(33):3045-3056. PubMed ID: 38750627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.
    Baber U; Dangas G; Angiolillo DJ; Cohen DJ; Sharma SK; Nicolas J; Briguori C; Cha JY; Collier T; Dudek D; Džavik V; Escaned J; Gil R; Gurbel P; Hamm CW; Henry T; Huber K; Kastrati A; Kaul U; Kornowski R; Krucoff M; Kunadian V; Marx SO; Mehta S; Moliterno D; Ohman EM; Oldroyd K; Sardella G; Sartori S; Shlofmitz R; Steg PG; Weisz G; Witzenbichler B; Han YL; Pocock S; Gibson CM; Mehran R
    Eur Heart J; 2020 Oct; 41(37):3533-3545. PubMed ID: 33085967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized evaluation of 5-month Ticagrelor monotherapy after 1-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with drug-coated balloons: REC-CAGEFREE II trial rationale and design.
    Gao C; Zhu B; Liu J; Jiang Z; Hu T; Wang Q; Liu Y; Yuan M; Li F; Zhang R; Xia J; Onuma Y; Wang D; Serruys P; Tao L;
    BMC Cardiovasc Disord; 2024 Jan; 24(1):62. PubMed ID: 38245724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
    Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
    Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Ticagrelor vs. Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention After Risk Stratification With the CHA
    Na K; Qiu M; Ma S; Li Y; Li J; Liu R; Zhang J; Han Y
    Front Cardiovasc Med; 2022; 9():808571. PubMed ID: 35445091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis.
    Dai L; Xu J; Jiang Y; Chen K
    Front Cardiovasc Med; 2022; 9():905607. PubMed ID: 35757353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS.
    Xue HJ; Shi J; Liu B; Wang DY; Dong ZX; Guo H; Kong YH; Sheng L; Shao Q; Sun DH; Zhang L; Pan YJ; Dong XW; Li JQ; Xue JY; Zhou YY; Yang HP; Li Y
    Platelets; 2016 Jul; 27(5):440-5. PubMed ID: 26830862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
    Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
    Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.
    Wang Y; Cavallari LH; Brown JD; Thomas CD; Winterstein AG
    JAMA Netw Open; 2023 Apr; 6(4):e238585. PubMed ID: 37067798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study).
    Liu GZ; Zhang S; Sun DH; Shi J; Bo WL; Wang WN; Zhang CY; Wang ZH; Feng W; He MJ; Liu YY; Li S; Zheng LQ; Li Y
    Eur J Clin Pharmacol; 2019 Aug; 75(8):1059-1068. PubMed ID: 31081522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.